Interfering with disease: a progress report on siRNA-based therapeutics
A de Fougerolles, HP Vornlocher… - Nature reviews Drug …, 2007 - nature.com
RNA interference (RNAi) quietly crept into biological research in the 1990s when
unexpected gene-silencing phenomena in plants and flatworms first perplexed scientists …
unexpected gene-silencing phenomena in plants and flatworms first perplexed scientists …
Progress towards in vivo use of siRNAs
MA Behlke - Molecular Therapy, 2006 - cell.com
RNA interference (RNAi) has become the method of choice to suppress gene expression in
vitro. It is also emerging as a powerful tool for in vivo research with over 90 studies …
vitro. It is also emerging as a powerful tool for in vivo research with over 90 studies …
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek, A Akinc, B Bramlage, K Charisse… - Nature, 2004 - nature.com
RNA interference (RNAi) holds considerable promise as a therapeutic approach to silence
disease-causing genes, particularly those that encode so-called 'non-druggable'targets that …
disease-causing genes, particularly those that encode so-called 'non-druggable'targets that …
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Delivery of small interfering RNAs (siRNAs) into cells is a key obstacle to their therapeutic
application. We designed a protamine-antibody fusion protein to deliver siRNA to HIV …
application. We designed a protamine-antibody fusion protein to deliver siRNA to HIV …
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
CN Landen Jr, A Chavez-Reyes, C Bucana… - Cancer research, 2005 - AACR
Inducing destruction of specific mRNA using small interfering RNA (siRNA) is a powerful tool
in analysis of protein function, but its use as a therapeutic modality has been limited by …
in analysis of protein function, but its use as a therapeutic modality has been limited by …
Fully 2 '-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA
CR Allerson, N Sioufi, R Jarres… - Journal of medicinal …, 2005 - ACS Publications
We have identified a small interfering RNA (siRNA) motif, consisting entirely of 2 '-O-methyl
and 2 '-fluoro nucleotides, that displays enhanced plasma stability and increased in vitro …
and 2 '-fluoro nucleotides, that displays enhanced plasma stability and increased in vitro …
Nonviral delivery of synthetic siRNAs in vivo
Sequence-specific gene silencing using small interfering RNA (siRNA) is a Nobel prize–
winning technology that is now being evaluated in clinical trials as a potentially novel …
winning technology that is now being evaluated in clinical trials as a potentially novel …
Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1
Background—Preeclampsia is characterized clinically by hypertension and proteinuria.
Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 …
Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 …
Efficient and targeted delivery of siRNA in vivo
MS Shim, YJ Kwon - The FEBS journal, 2010 - Wiley Online Library
RNA interference (RNAi) has been regarded as a revolutionary tool for manipulating target
biological processes as well as an emerging and promising therapeutic strategy. In contrast …
biological processes as well as an emerging and promising therapeutic strategy. In contrast …
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
A Santel, M Aleku, O Keil, J Endruschat, V Esche… - Gene therapy, 2006 - nature.com
For the application of RNA interference (RNAi) in vivo the functional delivery of short
interfering RNAs (siRNAs) is still the major obstacle. Therefore, delivery technologies need …
interfering RNAs (siRNAs) is still the major obstacle. Therefore, delivery technologies need …